NVAX earnings

GAITHERSBURG, Md., April 29, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, May 6, 2026. Details of the event and replay are as follows:Conference call details:Date:May 6, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can also dial direct to be enter

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areasMultiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major global pharmaceutical companies exploring the utility of Matrix-M for their vaccine portfolios Successful execution of Sanofi partnership with $225 million in milestones earned in full year 2025Total revenue of $147 million in the fourth quarter of 2025 and $1.1 billion for the full year 2025Continued advancement of early-stage pipeline with the intention to enter the clinic as early as 2027Year end 2025 Cash of $751 million Novavax exceeded its full year 2025 R&

GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

Total revenue of $70 million in the third quarter of 2025Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date including $50 million earned on marketing authorization transfersSanofi reported preliminary positive immunogenicity and safety Phase 1/2 data for Nuvaxovid™ in combination with both Fluzone High-Dose and FlublokSanofi received BARDA grant for pandemic influenza vaccine candidate using Novavax's Matrix-M® adjuvantMaryland site consolidation transactions resulted in $60 million cash proceeds and approximately $230 million in expected future cost savingsRaises Full Year 2025 Revenue Framework and Affirms Financial GuidanceCompany to

GAITHERSBURG, Md., Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November 6, 2025. Details of the event and replay are as follows: Conference call details:  Date:                                November 6, 2025 Time:                              8:30 a.m. ET URL to register phone:    Register Here Dial-in number:              (888) 880-3330 (U.S.) or (+1) (646) 357-8766 (International) Webcast:                        ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering thei

Total revenue of $239 million in the second quarter of 2025Received FDA BLA approval for Nuvaxovid™, the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S.; approval triggered $175 million milestone payment from SanofiCompleted transition of Nuvaxovid™ commercial leadership in the U.S. to Sanofi for the 2025-2026 COVID-19 vaccination season  COVID-19-Influenza-Combination and stand-alone influenza vaccine candidates showed robust immune responses in initial cohort of a Phase 3 trial with new T-cell response data in both Novavax vaccine candidates numerically higher than in the comparator Fluzone HD armUpdated Full Year 2025 Revenue Framework and Financial Guidanc

GAITHERSBURG, Md., July 30, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its second quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Wednesday, August 6, 2025. Details of the event and replay are as follows: Conference call details: Date: August 6, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: Register Here Dial-in number: (888) 880-3330 (Domestic) or (+1) (646) 357-8766 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can

FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDASHIELD-Utah study demonstrates that Nuvaxovid® resulted in fewer and less severe reactogenicity symptoms when compared to marketed mRNA vaccine; Nuvaxovid recipients experienced approximately 39% fewer symptoms on averageData presented at World Vaccine Congress showcases Matrix-M® utility when co-administered with a broad array of vaccine platforms and diseasesStrengthened partnership with Takeda in Japan, the third largest pharmaceutical market, with significant improvement in financial termsRaises full year 2025 revenue framework to between $975 mill

GAITHERSBURG, Md., May 1, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, May 8, 2025. Details of the event and replay are as follows: Conference call details: Date: May 8, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/43UHjFq Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants

Transitioned lead commercial responsibility of Nuvaxovid™ COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in the fourth quarter of 2024 and $682 million for the full year 2024 Achieved $50 million milestone under Sanofi agreement associated with the pediatric clinical trial database lock for the first cohortCompleted $200 million sale of Czech Republic manufacturing facility to Novo Nordisk; reduces annual costs by approximately $80 millionAdvanced pipeline programs, based on proven and innovative technology platformEnded full year 2024 with over $1 billion in Cash and accounts receivablesProvides 2025 financial guidance and revenue framew

GAITHERSBURG, Md., Feb. 20, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 27, 2025. Details of the event and replay are as follows: Conference call details: Date: February 27, 2025 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3PsP11e Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast:   ir.novavax.com/events Participants can join the conference call without operator assistance by regist

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidatesAchieved total revenue of $85 million in the third quarter of 2024 Ended the third quarter of 2024 with $1 billion in cash and receivablesReceived authorization from U.S. FDA and European Commission for updated 2024-2025 formula COVID-19 vaccine in individuals aged 12 and olderOutlined R&D strategy based on its proven technology platformUpdates full year 2024 financial guidanceCompany to host conference call today at 8:30 a.m. ETGAITHERSBURG, Md., Nov. 12, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-base

GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Tuesday, November 12, 2024. Details of the event and replay are as follows: Conference call details: Date: November 12, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3Y6irHG Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering

Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in CashFiled with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccineReceived $570 million in upfront payment and equity investment from Sanofi; progressed operationalization of Sanofi partnershipPhase 3 trial initiation for COVID-19-Influenza Combination and stand-alone influenza vaccines planned for Q4 2024; data expected by mid-2025Company to host conference call today at 8:30 a.m. ETGAITHERSBURG, Md., Aug. 8, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announc

GAITHERSBURG, Md., Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, August 8, 2024. Details of the event and replay are as follows: Conference call details: Date: August 8, 2024 Time: 8:30 a.m. U.S. ET URL to register phone: https://emportal.ink/3XTduSS Dial-in number: (800) 836-8184 (Domestic) or (+1) (646) 357-8785 (International) Webcast: ir.novavax.com/events  Participants can join the conference call without operator assistance by registering and entering the

Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a potential multi-billion dollar revenue opportunity for Novavax including:$500 million upfront payment Approximately $70 million equity investment in NovavaxUp to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royalties on product salesUp to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-MTM adjuvantAnnounces addition of standalone influenza vaccine to P

GAITHERSBURG, Md., May 7, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its first quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Friday, May 10, 2024. Details of the event and replay are as follows: Conference call details: Date:                              May 10, 2024 Time:                                8:30 a.m. U.S. ET URL to register phone:      https://emportal.ink/3VNP8J5 Dial-in number:                  (888) 664-6383 (Domestic) or (+1) (416) 764-8650 (International) Webcast:      ir.novavax.com/events Participants can join t

Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billionAccelerating progress toward expanding pipeline via Phase 3 COVID-19-Influenza Combination vaccine trial in second half 2024 and potential 2026 launchRescaled global footprint with 30% total headcount reduction as compared to Q1 2023Announced settlement with Gavi related to 2021 advance purchase agreement, removing financial uncertainty and enabling focus on shared public health mission Provided full year 2024 total revenue guidance of $800 million to $1 billionCompany to host conference call today at 8:30 a.m. ETGAITHERSBURG, Md., Feb. 28, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advanci

GAITHERSBURG, Md., Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Wednesday, February 28, 2024. Details of the event and replay are as follows: Conference call details: Date: February 28, 2024 Time: 8:30 a.m. U.S. EST URL to register phone: https://emportal.ink/3SqJSJv Dial-in number: (888) 664-6383 (Domestic) or (+1) (617) 892-4906 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistanc

GAITHERSBURG, Md., Aug. 1, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its second quarter 2023 financial results and operational highlights at 8:30 a.m. Eastern Daylight Time (EDT) on Tuesday, August 8, 2023. Details of the event and replay are as follows: Conference call details: Date:                                      August 8, 2023 Time:                                      8:30 a.m. U.S. EDT Dial-in number:                    (877) 883-0383 (Domestic) or (412) 902-6506 (International)  Passcode:                            1209328 Webcast:                           

Announced global restructuring and cost reduction initiative with expected 2024 full-year R&D and SG&A reduction of approximately 40% to 50% vs 2022Provided full year 2023 total revenue guidance of between $1.4 and $1.6 billionFirst quarter revenue reflects shift to seasonal demand pattern; on-track to deliver updated COVID vaccine for Fall seasonAnnounced positive Phase 2 topline results for COVID-Influenza Combination, standalone influenza, and high-dose COVID vaccine candidatesCompany to host conference call today at 8:30 a.m. ETGAITHERSBURG, Md., May 9, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, t

GAITHERSBURG, Md., May 2, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its first quarter 2023 financial results and operational highlights at 8:30 a.m. EDT on Tuesday, May 9, 2023. Details of the event and replay are as follows: Conference call details: Date: May 9, 2023 Time: 8:30 a.m. U.S. Eastern Daylight Time (EDT) Dial-in number: (877) 883-0383 (Domestic) or (412) 902-6506 (International)  Passcode: 3370620 Webcast: ir.novavax.com/events Participants will be prompted to request to join the Novavax, Inc. call.To ensure a timely connection, it is recommended that partic

Achieved revenues in fourth quarter 2022 of $357 million and full year 2022 of $2.0 billionAppointed John C. Jacobs as President and Chief Executive OfficerUpdated U.S. government agreement to include up to 1.5 million additional doses of Novavax's COVID-19 vaccine for delivery in 2023Expanded Nuvaxovid™ label in adult booster and adolescent primary seriesInitiated Phase 2 trial of COVID-19-Influenza Combination and stand-alone influenza vaccine candidatesCompany to host conference call today at 4:30 p.m. ETGAITHERSBURG, Md., Feb. 28, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced its fina

GAITHERSBURG, Md., Feb. 21, 2023 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a global vaccines company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2022 financial results and operational highlights on Tuesday, February 28, 2023, following the close of U.S. financial markets. Details of the event and replay are as follows: Conference call details: Date: February 28, 2023 Time: 4:30 p.m. U.S. Eastern Standard Time (EST) Dial-in number: (833) 974-2381 (Domestic) or (412) 317-5774 (International)  Webcast: ir.novavax.com/events Participants will be prompted to request to join the Novavax, Inc. call.To ensure

Achieved total revenue for the third quarter of $735 million Delivered over 94 million doses of NVX-CoV2373 globally to dateAuthorized as a booster for adults in the U.S., E.U., and additional markets Authorized as a primary series for adolescents aged 12 – 17 years in U.S., EU, Japan, and additional markets Announced data about our prototype's broad immune response against circulating variants when used as a booster Initiated NVX-CoV2373 Phase 2b/3 study in children 6 months through 11 years of ageRefining full year 2022 total revenue guidance to approximately $2.0 billionCompany to host conference call today at 4:30 p.m. ETGAITHERSBURG, Md., Nov. 8, 2022 /PRNewswire/ -- Novavax, Inc. (NASD

GAITHERSBURG, Md., Nov. 1, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2022 financial results and operational highlights on Tuesday, November 8, 2022, following the close of U.S. financial markets. Details of the event and replay are as follows: Conference call details: Date: November 8, 2022 Time: 4:30 p.m. U.S. Eastern Daylight Time (EDT) Dial-in number: 833) 974-2381 (Domestic) or (412) 317-5774 (International)  Webcast: ir.novavax.com/events Participants will be prompted to request to join the Novavax, Inc. ca

Received FDA EUA and CDC recommendation for NVX-CoV2373, marking the first protein-based COVID-19 vaccine authorized in the U.S. for adults; with immunizations underwayNuvaxovid™ and Covovax™ authorized for adults in 43 countries, with booster authorizations in Japan, Australia and New Zealand as well as, adolescent authorizations in the EU, Australia, India, Japan, and ThailandOver 73 million doses delivered globally to date Progressing variant program with top-line clinical data for Omicron expected near the end of the third quarter of 2022Adjusted revenue guidance to $2 billion to $2.3 billionCompany to host conference call today at 4:30 p.m. ETGAITHERSBURG, Md., Aug. 8, 2022 /PRNewswire/

GAITHERSBURG, Md., Aug. 1, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2022 financial results and operational highlights on Monday, August 8, 2022, following the close of U.S. financial markets. Details of the event and replay are as follows: Conference call details: Date:    August 8, 2022 Time:              4:30 p.m. U.S. Eastern Daylight Time (EDT) Dial-in number:          (833) 974-2381 (Domestic) or (412) 317-5774 (International)  Webcast:                    ir.novavax.com/events Participants will be prompte

Achieved revenue of $704 million and net income of $203 million highlighting the first profitable quarter as a commercial stage companyReiterating full year 2022 total revenue guidance of between $4 and $5 billionContinued label expansion including primary, booster and adolescent authorizations and new shipments of Nuvaxovid™ into European Union, Canada, South Korea, Australia Thailand, Singapore and New Zealand Submitted request for EUA to U.S. FDA for NVX-CoV2373, with FDA Advisory Committee meeting scheduled for June 7th Announced positive Phase 1/2 results of COVID-19-Influenza Combination vaccine candidate confirming feasibility of approach Company to host conference call today at 4:30

GAITHERSBURG, Md., May 2, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its first quarter 2022 financial results and operational highlights on Monday, May 9, 2022, following the close of U.S. financial markets. Details of the event and replay are as follows: Conference call details: Date: May 9, 2022 Time: 4:30 p.m. U.S. Eastern Daylight Time (EDT) Dial-in number: 833) 974-2381 (Domestic) or (412) 317-5774 (International)  Webcast: ir.novavax.com/events   Participants will be prompted to request to join the Novavax, Inc. call.To ensu

GAITHERSBURG, Md., Feb. 28, 2022 /PRNewswire/ -- NVX-CoV2373 is the first protein-based COVID-19 vaccine authorized in multiple major markets around the world, including the European Union, Australia, Canada, and Great Britain; authorizations granted by 12 regulatory agencies and emergency use listing from the WHO Additional filings for authorization under review, including in the United States Initiated vaccine shipments globally, with doses administered in the European Union, Australia, Indonesia and South Korea Expanded clinical body of evidence for NVX-CoV2373 across several studies, including: 82.5% overall protection against all COVID-19 infection in extended analysis of UK Phase 3 st

GAITHERSBURG, Md., Feb. 21, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its fourth quarter and full year 2021 financial results and operational highlights on Monday, February 28, 2022, following the close of U.S. financial markets. Details of the event and replay are as follows: Conference call details: Date: February 28, 2022 Time: 4:30 p.m. U.S. Eastern Standard Time (EST) Dial-in number: (877) 870-4263 (Domestic) or (412) 317-0790 (International)  Webcast: www.novavax.com/events • Participants will be prompted to request to jo

- PREVENT-19 pediatric expansion in adolescents aged 12 through 17 achieved primary effectiveness endpoint demonstrating comparability to adult population - Trial demonstrated 82% clinical efficacy against Delta variant - Immune responses were about two-to-three-fold higher in adolescents than in adults against all variants studied - Vaccine was well-tolerated with no safety signals identified - Novavax plans to supplement global regulatory filings with pediatric data in Q1 2022 - Company to host investor conference call today from 4:30 - 5:00 pm ET GAITHERSBURG, Md., Feb. 10, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializ

- Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants - Third dose produced increased immune responses comparable to or exceeding levels associated with protection in Phase 3 clinical trials, with a 9.3-fold IgG rise and a 19.9-fold ACE2 inhibition increase after booster dose - Immune responses in adolescents were 2- to 4-fold higher than adults against broad array of variants of interest and variants of concern - Development of Omicron-specific vaccine on track for initiation of GMP manufacturing in early January - Company to host investor conference call today from 4:30 - 5:00 pm ET GAITHERSBURG, Md., Dec. 2

GAITHERSBURG, Md., Nov. 4, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2021. "We are excited by the significant progress made over the quarter, including our landmark milestone of gaining the first regulatory approval for our COVID-19 vaccine," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "With additional regulatory submissions around the world, we are prepared to deliver our vaccine globally. We believe the highly encouraging resul

GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2021 financial results and operational highlights on Thursday, November 4, 2021, following the close of U.S. financial markets. Details of the event and replay are as follows: Conference call details: Date: November 4, 2021 Time: 4:30 p.m. U.S. Eastern Daylight Time (EDT) Dial-in number: (877) 870-426 (Domestic) or (412) 317-0790 (International)    Webcast: www.novavax.com/events Participants will be prompted to request to join the Novav

GAITHERSBURG, Md., Aug. 5, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the second quarter ended June 30, 2021. "We are highly encouraged by the filing of regulatory submissions in multiple markets, made in partnership with Serum Institute of India. We view these submissions as the first of many filings to come, which will allow NVX-CoV2373 to be made available at a global scale," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Our clinical successes over the second quarter reaffirm our confidence in NVX-

GAITHERSBURG, Md., May 10, 2021 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the first quarter ended March 31, 2021. "Novavax made great strides over the first quarter to pave the path for our COVID-19 vaccine candidate, NVX-CoV2373, notably achieving statistically significant efficacy across our Phase 3 UK and Phase 2b South Africa trials," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "In parallel, we have secured additional manufacturing and supply agreements, expanding our global supply chain to over 10 c

96% vaccine efficacy against original COVID-19 in UK Phase 3 trialVaccine cross-protection demonstrated against both variants circulating in the UK and South AfricaFull enrollment (~30,000 participants) in PREVENT-19 Phase 3 trialAgreements for ~300 million doses to dateAdditional 1.1 billion doses to be supplied to the COVAX Facility (jointly with Serum Institute of India)Clinical trial of variant strain vaccines as standalone and bivalent candidates expected mid-2021Company to host conference call today at 4:30 p.m. ET GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious

Pivotal Phase 3 trial in United Kingdom completes enrollmentPhase 2b efficacy trial in South Africa completes enrollment U.S./Mexico Phase 3 trial expected to begin in the coming weeks GAITHERSBURG, Md., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. NVX‑CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix‑M™. “Novavax is in a leading position to significantly contribute to the